These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 12800575)

  • 21. The stampede to convertibles.
    Jacobs T
    Nat Biotechnol; 2003 Aug; 21(8):855. PubMed ID: 12894195
    [No Abstract]   [Full Text] [Related]  

  • 22. When your stock takes a nosedive.
    Jacobs T
    Nat Biotechnol; 2006 Feb; 24(2):144. PubMed ID: 16465152
    [No Abstract]   [Full Text] [Related]  

  • 23. Gary Pisano.
    Pisano G
    Nat Biotechnol; 2011 Mar; 29(3):183. PubMed ID: 21390002
    [No Abstract]   [Full Text] [Related]  

  • 24. 25 top health care stocks. Will they lead the next market boom?
    Kane L
    Med Econ; 2001 Apr; 78(7):126-8, 133-6, 140-2. PubMed ID: 11368040
    [No Abstract]   [Full Text] [Related]  

  • 25. Sumitomo buys Oxford finance.
    Bouchie A
    Nat Biotechnol; 2004 Apr; 22(4):480. PubMed ID: 15085808
    [No Abstract]   [Full Text] [Related]  

  • 26. The 802 million dollars fallacy.
    Hodgson J
    Nat Biotechnol; 2004 Sep; 22(9):1076. PubMed ID: 15340464
    [No Abstract]   [Full Text] [Related]  

  • 27. Biotechnology partnerships--medicine for an ailing industry?
    DeLamarter J
    Nat Biotechnol; 2003 Aug; 21(8):847-8. PubMed ID: 12894192
    [No Abstract]   [Full Text] [Related]  

  • 28. Investors remain wary after first quarter downturn.
    Fletcher L
    Nat Biotechnol; 2002 May; 20(5):413-4. PubMed ID: 11981536
    [No Abstract]   [Full Text] [Related]  

  • 29. Paul Keckley.
    Keckley P
    Nat Biotechnol; 2011 Mar; 29(3):185. PubMed ID: 21390004
    [No Abstract]   [Full Text] [Related]  

  • 30. Investment indicators show US is still ahead.
    Lähteenmäki R; Hodgson J
    Nat Biotechnol; 1998 Feb; 16(2):149-50. PubMed ID: 9487519
    [No Abstract]   [Full Text] [Related]  

  • 31. Early-stage returns?
    Booth BL
    Nat Biotechnol; 2006 Nov; 24(11):1335-40. PubMed ID: 17093473
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A new prescription for your portfolio.
    Clifford L; O'Keefe B; Stires D
    Fortune; 2001 Jul; 144(2):74-6, 78, 80. PubMed ID: 11471357
    [No Abstract]   [Full Text] [Related]  

  • 33. Shutters come off IPO window.
    Hodgson J
    Nat Biotechnol; 2002 Jan; 20(1):6. PubMed ID: 11753342
    [No Abstract]   [Full Text] [Related]  

  • 34. Is there balm in Gilead?
    Jacobs T
    Nat Biotechnol; 2006 Dec; 24(12):1478. PubMed ID: 17160040
    [No Abstract]   [Full Text] [Related]  

  • 35. Russian fund steps up investments in innovative biotechs.
    Katsnelson A
    Nat Biotechnol; 2012 Jan; 30(1):9-11. PubMed ID: 22231078
    [No Abstract]   [Full Text] [Related]  

  • 36. Cancer pathways' target not validated by clinical results.
    Ratner M
    Nat Biotechnol; 1999 Mar; 17(3):220. PubMed ID: 10096279
    [No Abstract]   [Full Text] [Related]  

  • 37. Healthcare stocks soar on wings of restructuring.
    Lutz S
    Mod Healthc; 1996 Jan; 26(2):3. PubMed ID: 10153952
    [No Abstract]   [Full Text] [Related]  

  • 38. Sugen's strategy: a signal for P&U purchase.
    Glaser V
    Nat Biotechnol; 1999 Aug; 17(8):745-6. PubMed ID: 10429230
    [No Abstract]   [Full Text] [Related]  

  • 39. Biotechnology overview: where the industry is heading.
    Rothman E
    Healthspan; 1987 Oct; 4(9):19-24. PubMed ID: 10284965
    [No Abstract]   [Full Text] [Related]  

  • 40. Biotechnology mergers and acquisitions.
    Champsi FH
    Nat Biotechnol; 1998 May; 16 Suppl():61-2. PubMed ID: 9591276
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.